Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

17.32
-0.4300-2.42%
Post-market: 17.20-0.1200-0.69%19:58 EDT
Volume:478.92K
Turnover:8.34M
Market Cap:1.24B
PE:-4.91
High:17.89
Open:17.68
Low:17.19
Close:17.75
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.59
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5300
EPS(LYR):-3.5300
ROE:-60.78%
ROA:-33.92%
PB:4.06
PE(LYR):-4.91

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs

TIPRANKS
·
Feb 26

MoonLake Immunotherap Price Target Maintained With a $25.00/Share by Needham

Dow Jones
·
Feb 26

MoonLake posts FY 2025 interest expense of USD 7.2 million

Reuters
·
Feb 25

MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer

TIPRANKS
·
Feb 24

MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20

THOMSON REUTERS
·
Feb 24

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
Feb 24

Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept

MT Newswires Live
·
Feb 24

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Feb 24

BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase

Reuters
·
Feb 23

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk

Reuters
·
Feb 23

MoonLake Immunotherapeutics - Remaining Tranches Provide up to $400 Mln Future Funding - SEC Filing

THOMSON REUTERS
·
Feb 23

MoonLake Immunotherapeutics - Enters First Amendment to Loan and Security Agreement - SEC Filing

THOMSON REUTERS
·
Feb 23

MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study

MT Newswires Live
·
Feb 23

MoonLake announces results from Phase 2 trial of Sonelokimab

TIPRANKS
·
Feb 23

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Feb 23

MoonLake Q4 R&D expense USD 56 million, down 7.6%

Reuters
·
Feb 23

MoonLake Immunotherapeutics Confirms Investor Day Webcast Schedule With Open Q&A Session

Reuters
·
Feb 23

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

GlobeNewswire
·
Feb 23

MoonLake Immunotherap Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Feb 20